Immunotherapy
Immunomodulatory oligonucleotides as novel therapy for breast cancer
Published in Cancer Weekly, October 24th, 2006
"Oligonucleotides containing CpG motifs and IMO containing a synthetic immunostimulatory dinucleotide and a novel DNA structure have been suggested to have potential for the treatment of various human diseases. In the present study, a newly designed IMO was evaluated in several models of human (MCF-7 and BT474 xenograft) and murine (4T1 syngeneic) breast cancer," wrote H. Wang and colleagues, University of Alabama.
"Pharmacokinetics studies of the IMO administered by s.c., i.v., p.o., or i.p. routes were also accomplished....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-10-24)
More Articles from Cancer Weekly
- Breast Cancer
Breast cancer etiology linked to environmental causation - Complementary & Alternative Medicine
Prostate cancer sensitivity to doxorubicin-induced apoptosis mediated by Phellinus linteus - Hodgkin Lymphoma
Hodgkin lymphoma prevented by alcohol drinking - Mesothelioma & Lung Cancer
Mesothelioma and lung cancer risk increased with low plasma levels of retinol - Radiotherapy
Histone acetyltransferase inhibitors may increase sensitivity of tumors to radiation therapy - Acute Lymphoblastic Leukemia
Liposomal daunorubicin and cytarabine are effective as reinduction chemotherapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
